bs-83035C
[Life Science]
Idelalisib
DATASHEET
Formulation Off-white solid
Storage: -20°C
Product Information:
Potent (IC50 = 2.5nM) and selective (IC50’s: PI3Ka = 820nM, PI3Kb = 565nM, PI3Kg = 89nM) PI3Kd inhibitor.1,2 Useful clinical agent for the treatment of various blood cancers. Idelalisib attenuates regulatory T cells (Treg) but not conventional T cells (Tconv) resulting in a significant increase in tumor-infiltrating antigen-specific CD8 T cells in a murine lung cancer model.3 Conversely, systemic PI3Kd inactivation antagonized anti-CTLA-4 and anti-PD-L1 treatment.4 Others have found that Idelalisib minimally influenced rituximab- and obinutuzumab-mediated Ab-dependent cellular cytotoxicity in human lymphoma cells.5
Description:
CAS Number: 870281-82-6<br></br>Chemical Name: 5-Fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]quinazolin-4-one<br></br>Molecular weight: 415.43<br></br>Formula: C21H18FN7O<br></br>Solubility: DMSO (>25 mg/ml)<br></br>Physical Properties: White solid<br></br>Purity: >98% by HPLC NMR (Conforms)
Size: 10 mg, 50 mg10 mg, 50 mg
Applications: Life Science()
For research use only. Not intended for diagnostic or therapeutic use.